top of page
Gotham__Org Gotham White.png

Chemotherapy Convenience and Satisfaction Questionnaire



The Chemotherapy Convenience and Satisfaction Questionnaire (CCSQ) is comprised of two versions. The first is administered prior to initiating therapy and captures patients’ expectations on two domains: Chemotherapy Concerns (5 items) and Chemotherapy Convenience (3 items). The second version is administered while patients are on therapy (i.e., all post- Baseline Assessments) and includes three domains: Chemotherapy Concerns (5 items), Chemotherapy Convenience (3 items), and Chemotherapy Satisfaction (4 items). While its validity has been explored in multiple clinical trials, research into the relationship between the subscale scores and clinical variables should be explored in the future to further establish the measure’s validity.


Chemotherapy Convenience and Satisfaction Questionnaire (CCSQ)


3 - Baseline
6 - On Therapy


11 - Baseline
15 - On Therapy + Resource Utilization


Cancer patients 18 years and older receiving chemotherapy




5 point Likert-type scale


Paper and electronic


Self-administration and interview when applicable


Baseline: Chemotherapy Concerns, Chemotherapy Convenience
On Therapy: Chemotherapy Concerns, Chemotherapy Convenience, Chemotherapy Satisfaction


5-10 minutes


Manual scoring template, some items are reverse scored. Subscale scores and total scores possible.


Language Availability

Available translations of the CCSQ can be obtained by registering for permission. Users are not permitted to translate the CCSQ without permission from Permission from to translate the CCSQ may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.

Please contact us for more information.

Language Availability


Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.

Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.

To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.

Selected References

Selected References

Yost K., Hahn E., Cella D. A new measure of chemotherapy convenience and satisfaction: the CCSQ. Journal of Clinical Oncology 2005; 23:538a.

Saltz L., Badarinath S., Dakhil S., Bienvenu B., Harker W.G., Birchfield G., Tokaz L.K., Barrera D., Conkling P.R., O'Rourke M.A., Richards D.A., Reidy D., Solit D., Vakiani E., Capanu M., Scales A., Zhan F., Boehm K.A., Asmar L., Cohn A. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clinical Colorectal Cancer 2012; Jun 11(2):101-11.

Chua D.T., Yiu H.H., Seetalarom K., Ng A.W., Kurnianda J., Shotelersuk K., Krishnan G., Hong R.L., Yang M.H., Wang C.H., Sze W.K., Ng W.T. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head & Neck 2012; Sep 34(9):1225-30.

Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system.  Quality of Life Research 1996; 5: 309-320.

Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.

Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.

Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.

Related Measures

Related Measures


Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction – General


Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - Patient Satisfaction


Functional Assessment of Cancer Therapy - Cognitive Function

bottom of page